Speaker: John P. Overington, VP, Scientist - Exscientia, visiting professor - University College London, UK

Moderator: Mirian Hayashi, associate professor of Pharmacology at Escola Paulista de Medicina (EPM/Unifesp)

We are now in a data, compute and algorithm rich world, and still the discovery of new drugs is a major global challenge for many chronic diseases. It is clear though, that significant progress can be made, as evidenced by the rapid development and approval of novel small molecule and biological therapies for covid-19. The talk will detail the need for radical increases in productivity and speed, industrialisation and automation, and how machine learning approaches can address both target discovery and validation, and lead discovery and optimisation. Other opportunities for machine learning to make impact addressing drug combinations and acquired resistance in cancer and infectious disease are detailed.